Absolute monocyte/lymphocyte count prognostic score is independent of immunohistochemically determined cell of origin in predicting survival in diffuse large B-cell lymphoma

References

• Alizadeh AA, Eisen MB, Davis RE, . Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403:503–511.
   PubMed Web of Science ®Google Scholar
• Shipp MA, Ross KN, Tamayo P, . Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002;8:68–74.
   PubMed Web of Science ®Google Scholar
• Dave SS, Wright G, Tan B, . Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 2004;351:2159–2169.
   PubMed Web of Science ®Google Scholar
• Lenz G, Wright G, Dave SS, . Stromal gene signatures in large B-cell lymphoma. N Engl J Med 2008;359:2313–2323.
   PubMed Web of Science ®Google Scholar
• Cox MC, Nofroni I, Laverde G, . Absolute lymphocyte count is a prognostic factor in diffuse large B-cell lymphoma. Br J Haematol 2008;14:265–268.
   Google Scholar
• Kim DH, Baek JH, Chae YS, . Absolute lymphocyte count predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia 2007;21:2227–2230.
   PubMed Web of Science ®Google Scholar
• Oki Y, Yamamoto K, Kato H, . Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients’ survival benefit from rituximab. Eur J Haematol 2008;81:448–453.
   PubMed Web of Science ®Google Scholar
• Bari A, Marcheselli L, Sacchi S, . Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. Ann Oncol 2010;21:1486–1491.
   PubMed Web of Science ®Google Scholar
• Wilcox RA, Ristow K, Habermann TM, . The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large B-cell lymphoma. Leukemia 2011;25: 1502–1509.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, . Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103: 275–282.
   PubMed Web of Science ®Google Scholar
• Cox CJ, Habermann TM, Payne BA, . Evaluation of the Coulter counter model S-Plus IV. Am J Clin Pathol 1985;84:297–306.
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993;329:987–994.
   PubMed Web of Science ®Google Scholar
• Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
   Web of Science ®Google Scholar
• Cox DR. Regression models and life-tables. J R Stat Soc (B) 1972;34:187–202.
   Web of Science ®Google Scholar
• Gutierrez-Garcia G, Cordesa-Salzmann T, Climent F, . Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Blood 2011;117:4836–4843.
   PubMed Web of Science ®Google Scholar
• Monti S, Savage KJ, Kutok JL, . Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005;105:1851–1861.
   PubMed Web of Science ®Google Scholar
• Lin Y, Gustafson MP, Bulur PA, . Immunosuppressive CD14 + HLA-DRlow/-monocytes in B-cell non-Hodgkin's lymphoma. Blood 2011;117:872–881.
   PubMed Web of Science ®Google Scholar
• Song MK, Chung JS, Seol YM, . Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy. Ann Oncol 2010;21:140–144.
   PubMed Web of Science ®Google Scholar
• Fu K, Weisenburger DD, Choi WWL, . Addition of rituximab to standard chemotherapy improves the survival of both the germinal center B-cell-like and non-germinal center B-cell-like subtypes of diffuse large B-cell lymphoma. J Clin Oncol 2008;26:4587–4954.
   PubMed Web of Science ®Google Scholar
• Nyman H, Adde M, Karjalainen-Lindsberg ML, . Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007;109:4930–4935.
   PubMed Web of Science ®Google Scholar
• Wilcox RA, Wada DA, Ziesmer SC, . Monocytes promote tumor cell survival in T-cell lymphoproliferative disorders and are impaired in their ability to differentiate into mature dendritic sells. Blood 2009;114:2936–2944.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Stenson M, Habermann TM, . Cd4 + T-cell immune response to large B-cell non-Hodgkin's lymphoma predicts patient outcome. J Clin Oncol 2001;19:720–726.
   PubMed Web of Science ®Google Scholar
• Alizadeh AA, Gentles AJ, Alencar AJ, . Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment. Blood 2011;118:1350–1358.
   PubMed Web of Science ®Google Scholar
• Habermann TM, Wang SS, Maurer MF, . Host immune gene polymorphisms in combination with clinical and demographic factors predict late survival in diffuse large B-cell lymphoma in the pre-rituximab era. Blood 2008;112:2694–2702.
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, . CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma. N Engl J Med 2002;346:235–242.
   PubMed Web of Science ®Google Scholar